DMAC · DiaMedica Therapeutics Inc. · Documents

Nov 12

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Quarterly report for FY2026 Q3 AI summary on its way

Net loss $11.31M

Nov 12

Current report 8-K

Financial results AI summary on its way

Aug 11

Earnings call

Q2 2026 earnings call AI summary on its way

Aug 10

Current report 8-K

Financial results AI summary on its way

Aug 10

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Net loss $10.14M

May 21

Current report 8-K Events of May 20

Shareholder vote results AI summary on its way

May 19

Investor event

2026 RBC Capital Markets Global Healthcare Conference Fireside Chat AI summary on its way

May 7

Earnings call

Q1 2026 earnings call AI summary on its way

May 6

Current report 8-K

Financial results AI summary on its way

May 6

Quarterly report 10-Q FY2026 Q1, ended Mar 31

Quarterly report for FY2026 Q1 AI summary on its way

Net loss $10.04M

Apr 1

Proxy statement DEF 14A Meeting May 20, 2026

Proxy statement AI summary on its way

Apr 1

Annual report to holders ARS

Annual report to holders AI summary on its way

Apr 1

Proxy statement DEFA14A

Proxy statement AI summary on its way

Mar 31

Earnings call

Q4 2025 earnings call AI summary on its way

Mar 31

Current report 8-K Events of Mar 30

Financial results AI summary on its way

Mar 30

Annual report 10-K FY2025, ended Dec 31

Annual report for FY2025 AI summary on its way

Net loss $32.77M

Jan 5

Current report 8-K

Other events AI summary on its way

Dec 18

Current report 8-K

Regulation FD disclosure, Other events

Nov 12

Earnings call

Q3 2025 earnings call

Nov 12

Current report 8-K

Financial results

Nov 12

Quarterly report 10-Q FY2025 Q3, ended Sep 30

Quarterly report for FY2025 Q3

Net loss $8.62M

Aug 12

Current report 8-K

Financial results

Aug 12

Earnings call

Q2 2025 earnings call

Aug 12

Current report 8-K

Entered into a material agreement

Aug 12

Quarterly report 10-Q FY2025 Q2, ended Jun 30

Quarterly report for FY2025 Q2

Net loss $7.7M

Aug 12

Registration statement S-3

Registration statement

Aug 6

Current report 8-K Events of Aug 4

Director or officer change, or executive pay, Regulation FD disclosure, Other events

Aug 1

Registration statement S-3

Registration statement

Jul 21

Current report 8-K

Entered into a material agreement, Unregistered sale of equity, Other events

Jul 17

Current report 8-K

Regulation FD disclosure

May 15

Current report 8-K

Shareholder vote results

May 13

Earnings call

Q1 2025 earnings call

May 13

Current report 8-K

Financial results

May 13

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Net loss $7.71M

Mar 28

Proxy statement DEF 14A Meeting May 15, 2025

Proxy statement

Mar 28

Annual report to holders ARS

Annual report to holders

Mar 28

Proxy statement DEFA14A

Proxy statement

Mar 17

Earnings call

Q4 2024 earnings call

Mar 17

Current report 8-K

Financial results

Mar 17

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Net loss $24.44M

Mar 6

Current report 8-K Events of Feb 28

Director or officer change, or executive pay

Feb 24

Current report 8-K Events of Feb 20

Director or officer change, or executive pay, Regulation FD disclosure

Nov 13

Earnings call

Q3 2024 earnings call

Nov 13

Current report 8-K

Financial results, Regulation FD disclosure

Nov 13

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Net loss $6.27M

Aug 7

Earnings call

Q2 2024 earnings call

Aug 7

Current report 8-K

Financial results

Aug 7

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Net loss $5.12M

Jul 10

Registration statement S-3

Registration statement

Jun 26

Current report 8-K

Regulation FD disclosure, Other events